Definitive Healthcare (NASDAQ:DH) Updates Q2 2026 Earnings Guidance

Key Points

• Definitive Healthcare updated Q2 2026 guidance to EPS of 0.030–0.040 (vs. consensus 0.030) and revenue of $55.0–$56.0 million, and set FY 2026 EPS guidance at 0.160–0.19.
• The company beat Q1 estimates, reporting EPS of $0.06 versus a $0.03 consensus and revenue of $55.93 million (vs. $55.02 million), which underpins its guidance update.
• Shares trade around $0.92 with a market cap of about $97 million; analysts’ consensus rating is “Hold” with an average price target of $3.27, and institutional ownership is very high (98.67%) with Goldman Sachs notably increasing its stake.

Definitive Healthcare (NASDAQ:DH - Get Free Report) updated its second quarter 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.030-0.040 for the period, compared to the consensus estimate of 0.030. The company issued revenue guidance of $55.0 million-$56.0 million, compared to the consensus revenue estimate of $55.7 million. Definitive Healthcare also updated its FY 2026 guidance to 0.160-0.19 EPS.

Definitive Healthcare Price Performance

Shares of Definitive Healthcare stock traded down $0.02 on Thursday, hitting $0.92. The company's stock had a trading volume of 331,909 shares, compared to its average volume of 354,274. The company has a market capitalization of $97.23 million, a price-to-earnings ratio of -0.74, a price-to-earnings-growth ratio of 84.12 and a beta of 1.34. Definitive Healthcare has a 1 year low of $0.90 and a 1 year high of $4.70. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.64 and a current ratio of 1.64. The firm has a fifty day moving average price of $1.10 and a 200-day moving average price of $1.99.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.03. Definitive Healthcare had a positive return on equity of 2.63% and a negative net margin of 57.52%.The company had revenue of $55.93 million for the quarter, compared to the consensus estimate of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. As a group, sell-side analysts anticipate that Definitive Healthcare will post 0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DH has been the topic of a number of research analyst reports. Canaccord Genuity Group dropped their price target on shares of Definitive Healthcare from $4.00 to $3.00 and set a "hold" rating on the stock in a research note on Friday, February 27th. Barclays reduced their price objective on shares of Definitive Healthcare from $2.75 to $1.00 and set an "underweight" rating for the company in a research report on Monday, March 30th. Wall Street Zen upgraded shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, March 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Definitive Healthcare in a research note on Wednesday, January 21st. Finally, Zacks Research raised shares of Definitive Healthcare from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $3.27.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of DH. Goldman Sachs Group Inc. raised its stake in Definitive Healthcare by 564.2% during the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company's stock worth $25,191,000 after purchasing an additional 7,404,363 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Definitive Healthcare by 1.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company's stock valued at $8,417,000 after buying an additional 33,612 shares during the period. Arrowstreet Capital Limited Partnership lifted its holdings in Definitive Healthcare by 11.7% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company's stock valued at $4,937,000 after acquiring an additional 127,055 shares during the last quarter. Bank of America Corp DE grew its position in Definitive Healthcare by 23.7% in the second quarter. Bank of America Corp DE now owns 769,397 shares of the company's stock worth $3,001,000 after acquiring an additional 147,599 shares during the period. Finally, Inspire Investing LLC increased its stake in Definitive Healthcare by 505.7% during the fourth quarter. Inspire Investing LLC now owns 698,967 shares of the company's stock worth $2,006,000 after acquiring an additional 583,562 shares during the last quarter. Institutional investors and hedge funds own 98.67% of the company's stock.

About Definitive Healthcare

Definitive Healthcare NASDAQ: DH is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company's flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.